Plasmodium falciparum Merozoite Surface Protein 1 antigen (MSP1)

Plasmodium falciparum Merozoite Surface Protein 1 antigen (MSP1) is a large, surface-exposed protein complex consisting of four non-covalently associated fragments (p83, p30, p38, and p42)[1][2]. The complex is anchored to the parasite membrane via a glycosylphosphatidylinositol (GPI) anchor and is processed during erythrocyte invasion, leaving a conserved C-terminal 19-kDa domain (MSP1₁₉) exposed on the merozoite surface. This C-terminal region contains two epidermal growth factor (EGF)-like domains, crucial for red blood cell invasion[2][6]. MSP1 acts as a hub for interactions with other merozoite surface proteins and erythrocytes, mediating recognition and attachment required for invasion. Because antibodies against MSP1, especially MSP1₁₉, can neutralize parasite invasion, MSP1 remains a principal vaccine candidate antigen, although vaccine attempts are challenged by antigenic diversity and immune evasion mechanisms (e.g., blocking antibodies that interfere with protective antibody actions)[3][4][6]. MSP1 is not a human protein or a classical receptor, but a prototypical malarial target antigen. Its biological and structural features make it an essential mediator of Plasmodium infection and a focus of malaria vaccine research[1][3][6].

Other names

MSP1PfMSP1Merozoite Surface Protein 1MSP-1MSP-1 antigen

Inhibition of merozoite invasion via neutralizing antibodies; Antibody-mediated inhibition of MSP1 processing; Antigenic diversion (immune evasion mechanism by non-neutralizing antibodies)